Author

Grant H. Hickok

University of MinnesotaORCID 0009-0004-8235-4773Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Adam L. BurrackiD· 1 shared Alexander K. TsaiiD· 1 shared Ayaka Hulbert· 1 shared David MasopustiD· 1 shared Eduardo Cruz-HinojozaiD· 1 shared Guhan QianiD· 1 shared Hongrong ZhangiD· 1 shared Ingunn M. StromnesiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Adam L. BurrackORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Abrogating TGFβ signaling in TCR-engineered T cells and enhancing antigen processing by tumor cells promotes sustained therapeutic activity in pancreatic ductal adenocarcinoma

Alexander K. Tsai, Meagan R. Rollins, Madeline A. Ellefson, Zoe C. Schmiechen, Adam L. Burrack, Ayaka Hulbert, Guhan Qian, Hongrong Zhang, Eduardo Cruz-Hinojoza, Jonah Z. Butler, Jason S. Mitchell, Olivia C. Ghirardelli Smith, Stephen D. O’Flanagan, Jenny Krause, Grant H. Hickok, , Ingunn M. Stromnes

This study shows that blocking TGFβ signaling in TCR-engineered T cells and enhancing antigen processing in tumor cells improves their therapeutic effectiveness against pancreatic ductal adenocarcinoma.

Journal for ImmunoTherapy of Cancer · Oct 1, 2026Peer-reviewedImmunology